A major clinical trial has raised vital new questions regarding how physicians determine which patients should be prescribed statins to prevent heart attacks and strokes. Researchers discovered that utilizing heart scans to steer treatment decisions yielded the exact same observed rate of major cardiovascular events as traditional risk assessments. However, this approach achieved these results while generating far fewer recommendations to initiate statin therapy.
The findings, presented during a high-profile Hot Line session at the ESC Congress 2026, also uncovered a striking discrepancy in how consistently patients adhered to their medication regimens. Individuals who were advised to take statins based on the detection of calcium buildup in their coronary arteries proved to be substantially more likely to follow through with their treatment recommendations than those evaluated through standard screening methods.
Although these outcomes indicate that diagnostic heart scans could empower doctors to make more targeted and efficient treatment decisions, the trial ultimately did not establish that the scan-based approach was fully as effective as conventional risk assessment methodologies. Researchers point out that additional, larger-scale studies will be required to definitively determine whether imaging offers a superior overall strategy for preventing cardiovascular disease in the general population.
Why Predicting Heart Disease Risk Remains a Persistent Challenge
Cardiovascular disease remains the world’s leading cause of both illness and death. A vast majority of this global health burden stems from atherosclerotic cardiovascular disease, commonly known as ASCVD. This condition develops over time when fatty deposits, medical-term plaque, accumulate steadily on the inner walls of arteries. This buildup restricts normal blood flow and significantly increases the lifetime risk of experiencing debilitating heart attacks and strokes. Coronary artery disease and ischemic stroke stand out as two of the most prevalent and dangerous forms of this condition.
Several well-established risk factors significantly increase an individual’s likelihood of developing ASCVD. These include cigarette smoking, diabetes, high blood pressure, and elevated blood cholesterol levels. For decades, physicians have relied on these common clinical factors to estimate a person’s aggregate cardiovascular risk and to decide whether the introduction of preventive pharmaceutical interventions, such as statins, is appropriate.
Statins represent one of the most widely prescribed and thoroughly studied classes of medication used to lower that specific risk. These drugs work by lowering cholesterol levels in the bloodstream, particularly low-density lipoprotein cholesterol—frequently referred to as LDL or "bad" cholesterol. By reducing LDL levels, statins help lower the long-term likelihood of serious cardiovascular complications.
Despite the proven utility of these medications, identifying precisely which patients stand to benefit most from statin therapy remains a significant clinical challenge in modern medicine. Some individuals who eventually suffer a sudden heart attack do not appear to be at particularly high risk when evaluated using conventional screening methods and risk calculators.
"For far too many patients, the first symptom of ASCVD is a heart attack," said Dr. Joseph B. Muhlestein from the Intermountain Medical Center in Murray, USA, who served as the principal investigator of the CorCal Outcomes trial. "Statins have been shown to be highly effective in the prevention of ASCVD; however, there is a major gap in risk assessment, statin initiation, and statin persistence."
According to Dr. Muhlestein, many individuals who suffer their initial heart attack—particularly younger adults—would not have previously been classified as having a sufficient level of cardiovascular risk to justify the routine initiation of statin treatment. This inherent limitation in traditional screening tools has prompted clinical researchers to investigate whether directly examining the anatomical state of the arteries might provide much more useful, actionable information.
Can Heart Calcium Scans Improve Statin Decisions?
The CorCal Outcomes trial was explicitly designed to investigate two different clinical approaches for determining which patients should be advised to begin statin therapy before they ever experience a symptomatic cardiovascular event.
The first approach relied upon the pooled cohort equations, a widely utilized risk assessment tool that estimates an individual’s ten-year cardiovascular risk using traditional factors such as age, total cholesterol levels, blood pressure measurements, and smoking status.
The second approach measured coronary artery calcium, which provides a much more direct physical indication of underlying plaque buildup within the major arteries supplying oxygen-rich blood to the heart muscle itself.
This specific measurement is obtained using a specialized computed tomography, or CT, scan designed to detect microscopic calcium deposits within the coronary arteries. Calcium frequently accumulates within maturing atherosclerotic plaque over time, making it a highly reliable diagnostic marker of underlying coronary artery disease, even in asymptomatic people who have not yet developed clinical warning signs.
Unlike traditional risk calculators, which merely estimate the statistical probability of future cardiovascular problems based on general personal characteristics and routine health measurements, coronary calcium scans provide direct physical evidence of disease already present in the coronary arteries.
The clinical researchers wanted to determine whether incorporating this direct anatomical information into routine statin recommendations could successfully improve overall cardiovascular outcomes over time.
Nearly 5,800 Patients Put Both Methods to the Test
The clinical trial successfully enrolled 5,772 participants recruited from the Canyons and Desert regions of Intermountain Health Care in the United States. To be eligible for participation, individuals had to have no known history of prior ASCVD or diabetes, and they must not have previously received any form of statin therapy.
The average age of the study participants was 64 years old, and women accounted for 51% of the total study population, ensuring a well-balanced demographic representation.
Eligible participants were randomly assigned in a 1:1 ratio to one of two distinct study groups. One group received statin treatment guidance based entirely on traditional cardiovascular risk scores, while the other group received treatment recommendations generated solely from the results of their coronary calcium scans.
Both the participating patients and their primary physicians were fully informed of the specific treatment recommendations generated by the study protocol. However, the final clinical decision regarding whether or not to actually start taking statins was left entirely in the hands of the patients and their personal doctors, mirroring real-world medical practice.
The researchers subsequently tracked the occurrence of major adverse cardiovascular events among all participants. This combined clinical endpoint, known as MACE, encompassed all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, and arterial revascularization procedures.
This comprehensive composite outcome included death from any cause, heart attacks, strokes, and medical interventions specifically performed to restore normal blood flow through narrowed or obstructed arteries.
Heart Scans Led to Far Fewer Statin Recommendations
After following the study cohort for an average duration of 4.2 years, the researchers discovered that major cardiovascular events occurred at precisely the same observed rate in both of the study arms.
A total of 2.7% of patients in each respective group experienced at least one of the clinical events included in the study’s primary composite outcome. The estimated relative risk over time was also remarkably identical, demonstrating a hazard ratio of 0.99 with a 95% confidence interval ranging from 0.71 to 1.38, and a p-value of 0.045 for non-inferiority.
However, this statistical similarity in event rates did not formally establish that the two distinct prevention strategies were equally effective. The study ultimately failed to meet its pre-determined statistical requirement for definitively proving that the calcium scan-guided approach was not meaningfully worse than conventional risk assessment.
Despite this nuance, a striking and notable difference quickly emerged regarding how frequently patients were advised by the protocol to begin taking statins in the first place.
Participants who were evaluated using traditional risk scores received recommendations to start statin therapy more than three times as often as those whose treatment decisions were guided by coronary artery calcium measurements.
Despite this massive discrepancy in the volume of treatment recommendations generated, both groups ultimately experienced the exact same observed rate of major cardiovascular events throughout the duration of the follow-up period.
A Surprising Difference in Statin Adherence
Perhaps the most intriguing and clinically unexpected finding involved whether patients actually followed through with their prescribed preventative treatment plans after leaving the clinic.
Among the subset of individuals who were officially advised to take statins, patients whose recommendations were based on coronary calcium scans proved to be significantly more likely to adhere consistently to their daily medication regimen than those who were assessed using traditional cardiovascular risk factors alone.
The scale of this difference was substantial, standing at 62% adherence in the scan-guided group compared to just 23% in the traditional risk score group.
In practical terms, patients who received statin recommendations backed by visible, tangible evidence of calcium buildup within their own coronary arteries were approximately 2.7 times as likely to faithfully maintain their medication regimen over the long term.
One leading hypothesis among researchers is that witnessing concrete, physical evidence of disease residing directly inside their own arteries serves as a powerful psychological motivator for patients, encouraging them to take preventative medications much more seriously. However, the trial protocol was not designed to definitively establish the underlying psychological or behavioral reasons why adherence differed so dramatically between the two cohorts.
These findings raise the distinct possibility that incorporating coronary calcium scans into routine practice could profoundly influence not only which specific patients receive statin recommendations, but also whether those patients stay motivated to consistently consume the life-saving medications.
What the Findings Mean for Heart Disease Prevention
Despite these potentially important behavioral differences, the researchers heavily emphasized that the trial could not definitively establish whether calcium scan-guided treatment provides a level of cardiovascular protection that is truly comparable to traditional risk assessment methods.
One critical limitation noted by the investigators was that a significantly smaller number of participants experienced major cardiovascular events during the study than the research team had originally anticipated. With fewer total events available to analyze, the trial possessed less overall statistical power to determine whether a clinically meaningful difference truly existed between the two competing approaches.
"The power of the study to detect a difference was reduced by the lower-than-expected event rates and we did not demonstrate noninferiority between the groups," Dr. Muhlestein stated. He concluded that the study nonetheless "provided important hypothesis-generating insights into the efficiency of statin initiation and adherence when decisions are based on CAC scoring. Taken together, our data could be used to plan an additional well-powered randomized trial comparing CAC with current risk factor-based algorithms."
These insights may prove instrumental in helping clinical researchers design future, larger-scale trials capable of definitively determining whether coronary calcium scans can successfully streamline and improve the efficiency of statin prescribing practices without ever compromising the level of cardiovascular protection afforded to patients.
Current European clinical recommendations already recognize a potential diagnostic role for these measurements in select populations. The 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias officially recommends considering increased coronary calcium scores, when accessible, as an additional modifying factor in routine cardiovascular risk assessment.
This clinical guidance applies particularly to individuals categorized as being at moderate cardiovascular risk, or to those whose estimated risk falls closely near the standard medical threshold at which preventive statin therapy would normally be recommended by guidelines.
For these specific individuals, having concrete evidence of coronary calcium buildup may assist physicians in making much more informed, personalized treatment decisions during clinical encounters where the absolute necessity of statin therapy remains uncertain.
The findings from the CorCal Outcomes trial add significant new data to this ongoing clinical discussion by demonstrating that heart scans may also heavily influence how faithfully patients adhere to their prescribed treatments over time. Whether that behavioral advantage ultimately translates into superior long-term cardiovascular outcomes remains an important question that future scientific research must answer.